文献速递妇科

子宫内膜癌预后分层RNAseq特征谱的建立与验证

Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2022-01-13

研究基于TCGA数据(543例)用LASSO惩罚Cox模型建立预后特征谱,并在两院2010—2017年收治的I—IV期患者中验证。38基因特征谱预测疾病特异性生存的AUC为0.80,联合TP53突变亚组与RNAseq特征的复合分类器可独立区分三个预后等级,模型AUC为0.84优于0.76。

要点

  • 38基因RNAseq特征谱预测子宫内膜癌疾病特异性生存,AUC为0.80。
  • 复合分类器识别三个独立预后等级:RNAseq预后好(参照)、非TP53突变但RNAseq预后差(aHR=5.75)、TP53突变亚组(aHR=5.64)。
  • 联合高危组与复合分类器的模型预测AUC=0.84,优于不含复合分类器的AUC=0.76(p=0.01)。

核心结论

  • RNAseq分析可为现有分类系统提供额外预后信息,并值得验证以探索基于RNAseq的治疗策略。

研究设计与样本

  • 在TCGA队列(N=543例患者)上以LASSO惩罚Cox模型训练识别预后特征谱。
  • 开发基于polyA-RNAseq的临床可行工作流程,在两所医院2010—2017年收治的I—IV期患者队列中进行外部验证。
  • 采用时间依赖ROC曲线评估模型对疾病特异性生存(DSS)的预测性能。
  • 通过多变量Cox模型评估RNAseq特征谱的附加价值,校正高危预后组(2021 ESGO-ESTRO-ESP指南:非子宫内膜样组织学或III—IVA期或TP53突变分子亚组)。

主要发现

  • 外部验证队列纳入209例患者,其中错配修复缺陷61例(30%)、POLE突变10例(5%)、TP53突变52例(25%)、无特定分子谱82例(40%)。
  • 38基因特征谱准确预测DSS,AUC=0.80。
  • 多数疾病相关死亡发生于高危患者,高危患者5年DSS=78%(95%CI[68%-89%]),无高危患者5年DSS=99%(95%CI[97%-100%])。
  • 复合分类器识别三个与DSS独立相关的类别:RNAseq预后好(参照,5年DSS=99%)、非TP53突变但RNAseq预后差(aHR=5.75,95%CI[1.14-29.0])、TP53突变亚组(aHR=5.64,95%CI[1.12-28.3])。
  • 联合高危组与复合分类器的模型预测DSS的AUC=0.84,不含复合分类器的模型AUC=0.76(p=0.01)。

关键数值与推荐

  • 38基因RNAseq特征谱预测DSS的AUC=0.80。
  • 高危患者5年DSS=78%(95%CI[68%-89%]),无高危患者5年DSS=99%(95%CI[97%-100%])。
  • 非TP53突变但RNAseq预后差组aHR=5.75(95%CI[1.14-29.0]),TP53突变亚组aHR=5.64(95%CI[1.12-28.3]),参照为RNAseq预后好组(5年DSS=99%)。
  • 联合高危组与复合分类器的模型AUC=0.84,不含复合分类器的模型AUC=0.76(p=0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite recent advances in endometrial carcinoma (EC) molecular characterization, its prognostication remains challenging. We aimed to assess whether RNAseq could stratify EC patient prognosis beyond current classification systems. METHODS: A prognostic signature was identified using a LASSO-penalized Cox model trained on TCGA (N = 543 patients). A clinically applicable polyA-RNAseq-based work-flow was developed for validation of the signature in a cohort of stage I-IV patients treated in two Hospitals [2010-2017]. Model performances were evaluated using time-dependent ROC curves (prediction of disease-specific-survival (DSS)). The additional value of the RNAseq signature was evaluated by multivariable Cox model, adjusted on high-risk prognostic group (2021 ESGO-ESTRO-ESP guidelines: non-endometrioid histology or stage III-IVA orTP53-mutated molecular subgroup). RESULTS: Among 209 patients included in the external validation cohort, 61 (30%), 10 (5%), 52 (25%), and 82 (40%), had mismatch repair-deficient, POLE-mutated, TP53-mutated tumors, and tumors with no specific molecular profile, respectively. The 38-genes signature accurately predicted DSS (AUC = 0.80). Most disease-related deaths occurred in high-risk patients (5-years DSS = 78% (95% CI = [68%-89%]) versus 99% [97%-100%] in patients without high-risk). A composite classifier accounting for the TP53-mutated subgroup and the RNAseq signature identified three classes independently associated with DSS: RNAseq-good prognosis (reference, 5-years DSS = 99%), non-TP53 tumors but with RNAseq-poor prognosis (adjusted-hazard ratio (aHR) = 5.75, 95% CI[1.14-29.0]), and TP53-mutated subgroup (aHR = 5.64 [1.12-28.3]). The model accounting for the high-risk group and the composite classifier predicted DSS with AUC = 0.84, versus AUC = 0.76 without (p = 0.01). CONCLUSION: RNA-seq profiling can provide an additional prognostic information to established classification systems, and warrants validation for potential RNAseq-based therapeutic strategies in EC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Beinse G, Le Frere Belda MA, Just PA, et al. Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. Gynecol Oncol. 2022. PMID: 35033379. doi:10.1016/j.ygyno.2022.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。